CRC1366
Vascular Control of Organ Function
Prof. Dr. Moritz Felcht
Associated member 2021-2022 | Project AP
Department of Dermatology, Venereology and Allergology
European Center for Angioscience (ECAS)
Medical Faculty Mannheim, Heidelberg University
Professional Career
Since 2020
Managing Chief Physician
Department of Dermatology, Venereology and Allergology
Medical Faculty Mannheim, Heidelberg University, Germany
Since 2017
Member of the Executive Board
German Society of Dermatosurgery (DGDC)
Since 2015
Consultant Physician, Head of Division
Division of Dermatosurgery, Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Heidelberg University
2013 - 2015
Junior Consultant Physician, Sub-Head of Division
Division of Dermatosurgery, Department of Dermatology, Venereology and
Allergology, University Medical Center Mannheim, Heidelberg University
Since 2013
Research Project Leader
Vascular Tumor Microenvironment Group, Department of Dermatology,
Venereology and Allergology, University Medical Center Mannheim, Heidelberg University
2008 - 2013
Postdoctoral Fellow
Division of Vascular Oncology and Metastasis
German Cancer Research Center (DKFZ), Heidelberg
2007 - 2012
Resident Physician
Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Heidelberg University
2007
Resident Physician
Department of General and Vascular Surgery
University of Lübeck, Germany
2007
Dr. med.
Selected Publications
Gengenbacher N*, Singhal M*, Mogler C, Hai L, Milde L, Pari AAA, Besemfelder E, Fricke C, Baumann D, Gehrs S, Utikal J, Felcht M, Hu J, Schlesner M, Offringa R, Chintharlapalli SR, Augustin HG: Timed Ang2-targeted therapy identifies the Angiopoietin-Tie pathway as key regulator of fatal lymphogenous metastasis. Cancer Discovery. 11:424-45, 2021 (*equal contribution).
Abdul Pari AA, Singhal M, Hübers C, Mogler C, Schieb B, Gampp A, Gengenbacher N, Reynolds LE, Terhardt D, Géraud C, Utikal J, Thomas M, Goerdt S, Hodivala-Dilke KM, Augustin HG*, Felcht M*: Tumor cell-derived Angiopoietin-2 promotes metastasis in melanoma. Cancer Res. 80:2586-96, 2020 (*equal contribution).
Felcht M, Benecke J, Reiners-Koch P: “The Flap Finder”. Springer Medizin https://www.springermedizin.de/ flapfinder, online since Dec. 2020.
Bauer C, Abdul Pari AA, Umansky V, Utikal J, Boukamp P, Augustin HG, Goerdt S, Géraud* C, Felcht M*: T-lymphocyte profiles differ between keratoacanthomas and invasive squamous cell carcinomas of the skin. Cancer Immunol Immunother. 67:1147-57, 2018 (*equal contribution).
Teichert M*, Stumpf C*, Booken N, Wobser M, Nashan D, Hallermann C, Mogler C, Müller CS, Becker JC, Moritz RK, Andrulis M, Nicolay JP, Goerdt S, Thomas M, Klemke CD, Augustin HG, Felcht M: Aggressive primary cutaneous B-cell lymphomas show increased Angiopoietin-2-induced angiogenesis. Exp Dermatol. 24:424-9, 2015 (*equal contribution).
Felcht M, Thomas M: Angiogenesis in malignant melanoma. J Dtsch Dermatol Ges. 13: 125-36, 2015.
Felcht M, Heck M, Weiss C, Becker JC, Dippel E, Müller CS, Nashan D, Sachse MM, Nicolay MP, Booken N, Goerdt S, Klemke CD: Expression of the T-cell regulatory marker FOXP3 in primary cutaneous large B-cell lymphoma tumor cells. Brit J Dermatol. 167:348-58, 2012.
Felcht M, Luck R, Schering A, Seidel P, Srivastava K, Hu J, Bartol A, Kienast Y, Vettel C, Loos EK, Kutschera S, Bartels P, Appak S, Besemfelder E, Terhardt D, Chavakis E, Wieland T, Klein C, Thomas M, Uemura A, Goerdt S, Augustin HG: Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signalling. J Clin Invest. 122:1991-2005, 2012.
Felcht M, N Booken, P Ströbel, S Goerdt, CD Klemke: The value of molecular diagnostics in primary cutaneous B-cell lymphomas in the context of clinic, histology and immunohistochemistry. J Am Acad Dermatol. 25: 788-93, 2011.
Thomas M*, Felcht M*, Kruse K, Kretschmer S, Deppermann C, Biesdorf A, Rohr K, Benest AV, Fiedler U, Augustin HG: Angiopoietin-2 stimulation of endothelial cells ind-uces αvβ3 integrin internalization and degradation. J Biol Chem. 285:23842-9, 2010 (*equal contribution).